“Dual Neutralization of IL-17A and IL-17F With Bimekizumab Improves Quality of Life in Patients Withmoderate-to-Severe Plaque Psoriasis: Results from a Phase 2b Study and Correlation With Clinical Response”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S92. https://doi.org/10.25251/skin.2.supp.93.